Metagenomi Therapeutics (MGX) Change in Receivables (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Change in Receivables of -$305000.0 for Q1 2026, down 24.49% year-over-year from -$403918.9 in Q1 2025, and up 53.44% quarter-over-quarter from -$655000.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Change in Receivables (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Change in Receivables for 4 consecutive years, with -$305000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 24.49% year-over-year to -$305000.0; the TTM figure through Mar 2026 stood at -$1.0 million (up 5.42% YoY), while the FY2025 annual figure was -$952000.0, up 20.27% from the prior year.
- Change in Receivables rose to -$305000.0 in Q1 2026 per MGX's latest filing, from -$655000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $1.6 million in Q3 2023 and bottomed at -$1.5 million in Q4 2023.
- Historically, Change in Receivables has averaged -$211636.4 across 4 years, with a median of -$305000.0 in 2026.
- Annual changes were most pronounced in 2024 — Change in Receivables jumped 145.35% — and 2025, when it tumbled 198.05%.
- Metagenomi Therapeutics' Change in Receivables stood at -$1.5 million in 2023, then surged by 145.35% to $668000.0 in 2024, then tumbled by 198.05% to -$655000.0 in 2025, then jumped by 53.44% to -$305000.0 in 2026.
- Business Quant data shows MGX's Change in Receivables at -$305000.0 in Q1 2026, -$655000.0 in Q4 2025, and $87000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -305,000.00 |
| Mar 31, 2026 | -305,000.00 |
| Dec 31, 2025 | -655,000.00 |
| Dec 31, 2025 | -655,000.00 |
| Sep 30, 2025 | 87,000.00 |
| Sep 30, 2025 | 87,000.00 |
| Jun 30, 2025 | -139,000.00 |
| Jun 30, 2025 | -139,000.00 |
| Mar 31, 2025 | -245,000.00 |
| Mar 31, 2025 | -245,000.00 |
| Dec 31, 2024 | 668,000.00 |
| Dec 31, 2024 | 668,000.00 |
| Sep 30, 2024 | -1.06 Mn |
| Sep 30, 2024 | -1.06 Mn |
| Jun 30, 2024 | -434,000.00 |
| Jun 30, 2024 | -434,000.00 |
| Mar 31, 2024 | -369,000.00 |
| Mar 31, 2024 | -369,000.00 |
| Dec 31, 2023 | -1.47 Mn |
| Dec 31, 2023 | -1.47 Mn |